Hosted on MSN15d
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. The ...
Hosted on MSN11d
Jim Cramer on Eli Lilly and Company (LLY)’s Q4 2024 Performance: ‘Aren’t As Strong As Wall Street Was Hoping’We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...
Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...
Earnings Report 5.212 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.918 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.695 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...
On Tuesday, Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full ... contributed to our Q4 results. We continued to make progress on our manufacturing build-out, and U.S. supply ...
Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Eli Lilly and ...
JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...
Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback